Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma

Daniel Tusé, Nora Ku, Maurizio Bendandi, Carlos Becerra, Robert Collins, Nyla Langford, Susana Inogés Sancho, Ascensión López-Díaz De Cerio, Fernando Pastor, Romy Kandzia, Frank Thieme, Franziska Jarczowski, Dieter Krause, Julian K C Ma, Shan Pandya, Victor Klimyuk, Yuri Gleba, John E. Butler-Ransohoff

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We report the first evaluation of plant-made conjugate vaccines for targeted treatment of B-cell follicular lymphoma (FL) in a Phase I safety and immunogenicity clinical study. Each recombinant personalized immunogen consisted of a tumor-derived, plant-produced idiotypic antibody (Ab) hybrid comprising the hypervariable regions of the tumor-associated light and heavy Ab chains, genetically grafted onto a common human IgG1 scaffold. Each immunogen was produced in Nicotiana benthamiana plants using twin magnICON vectors expressing the light and heavy chains of the idiotypic Ab. Each purified Ab was chemically linked to the carrier protein keyhole limpet hemocyanin (KLH) to form a conjugate vaccine. The vaccines were administered to FL patients over a series of ≥ 6 subcutaneous injections in conjunction with the adjuvant Leukine (GM-CSF). The 27 patients enrolled in the study had previously received non-anti-CD20 cytoreductive therapy followed by ≥ 4 months of immune recovery prior to first vaccination. Of 11 patients who became evaluable at study conclusion, 82% (9/11) displayed a vaccine-induced, idiotype-specific cellular and/or humoral immune response. No patients showed serious adverse events (SAE) related to vaccination. The fully scalable plant-based manufacturing process yields safe and immunogenic personalized FL vaccines that can be produced within weeks of obtaining patient biopsies.

Original languageEnglish (US)
Article number648143
JournalBioMed Research International
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Plant Tumors
Conjugate Vaccines
Follicular Lymphoma
Tumors
Safety
Vaccines
Antibodies
Vaccination
Biopsy
Granulocyte-Macrophage Colony-Stimulating Factor
Light
Scaffolds
B-Cell Lymphoma
Subcutaneous Injections
Humoral Immunity
Carrier Proteins
Cellular Immunity
Immunoglobulin G
Cells
Tobacco

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma. / Tusé, Daniel; Ku, Nora; Bendandi, Maurizio; Becerra, Carlos; Collins, Robert; Langford, Nyla; Sancho, Susana Inogés; López-Díaz De Cerio, Ascensión; Pastor, Fernando; Kandzia, Romy; Thieme, Frank; Jarczowski, Franziska; Krause, Dieter; Ma, Julian K C; Pandya, Shan; Klimyuk, Victor; Gleba, Yuri; Butler-Ransohoff, John E.

In: BioMed Research International, Vol. 2015, 648143, 2015.

Research output: Contribution to journalArticle

Tusé, D, Ku, N, Bendandi, M, Becerra, C, Collins, R, Langford, N, Sancho, SI, López-Díaz De Cerio, A, Pastor, F, Kandzia, R, Thieme, F, Jarczowski, F, Krause, D, Ma, JKC, Pandya, S, Klimyuk, V, Gleba, Y & Butler-Ransohoff, JE 2015, 'Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma', BioMed Research International, vol. 2015, 648143. https://doi.org/10.1155/2015/648143
Tusé, Daniel ; Ku, Nora ; Bendandi, Maurizio ; Becerra, Carlos ; Collins, Robert ; Langford, Nyla ; Sancho, Susana Inogés ; López-Díaz De Cerio, Ascensión ; Pastor, Fernando ; Kandzia, Romy ; Thieme, Frank ; Jarczowski, Franziska ; Krause, Dieter ; Ma, Julian K C ; Pandya, Shan ; Klimyuk, Victor ; Gleba, Yuri ; Butler-Ransohoff, John E. / Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma. In: BioMed Research International. 2015 ; Vol. 2015.
@article{0334a3d2efdc474a891cdaaf7e1329ae,
title = "Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma",
abstract = "We report the first evaluation of plant-made conjugate vaccines for targeted treatment of B-cell follicular lymphoma (FL) in a Phase I safety and immunogenicity clinical study. Each recombinant personalized immunogen consisted of a tumor-derived, plant-produced idiotypic antibody (Ab) hybrid comprising the hypervariable regions of the tumor-associated light and heavy Ab chains, genetically grafted onto a common human IgG1 scaffold. Each immunogen was produced in Nicotiana benthamiana plants using twin magnICON vectors expressing the light and heavy chains of the idiotypic Ab. Each purified Ab was chemically linked to the carrier protein keyhole limpet hemocyanin (KLH) to form a conjugate vaccine. The vaccines were administered to FL patients over a series of ≥ 6 subcutaneous injections in conjunction with the adjuvant Leukine (GM-CSF). The 27 patients enrolled in the study had previously received non-anti-CD20 cytoreductive therapy followed by ≥ 4 months of immune recovery prior to first vaccination. Of 11 patients who became evaluable at study conclusion, 82{\%} (9/11) displayed a vaccine-induced, idiotype-specific cellular and/or humoral immune response. No patients showed serious adverse events (SAE) related to vaccination. The fully scalable plant-based manufacturing process yields safe and immunogenic personalized FL vaccines that can be produced within weeks of obtaining patient biopsies.",
author = "Daniel Tus{\'e} and Nora Ku and Maurizio Bendandi and Carlos Becerra and Robert Collins and Nyla Langford and Sancho, {Susana Inog{\'e}s} and {L{\'o}pez-D{\'i}az De Cerio}, Ascensi{\'o}n and Fernando Pastor and Romy Kandzia and Frank Thieme and Franziska Jarczowski and Dieter Krause and Ma, {Julian K C} and Shan Pandya and Victor Klimyuk and Yuri Gleba and Butler-Ransohoff, {John E.}",
year = "2015",
doi = "10.1155/2015/648143",
language = "English (US)",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma

AU - Tusé, Daniel

AU - Ku, Nora

AU - Bendandi, Maurizio

AU - Becerra, Carlos

AU - Collins, Robert

AU - Langford, Nyla

AU - Sancho, Susana Inogés

AU - López-Díaz De Cerio, Ascensión

AU - Pastor, Fernando

AU - Kandzia, Romy

AU - Thieme, Frank

AU - Jarczowski, Franziska

AU - Krause, Dieter

AU - Ma, Julian K C

AU - Pandya, Shan

AU - Klimyuk, Victor

AU - Gleba, Yuri

AU - Butler-Ransohoff, John E.

PY - 2015

Y1 - 2015

N2 - We report the first evaluation of plant-made conjugate vaccines for targeted treatment of B-cell follicular lymphoma (FL) in a Phase I safety and immunogenicity clinical study. Each recombinant personalized immunogen consisted of a tumor-derived, plant-produced idiotypic antibody (Ab) hybrid comprising the hypervariable regions of the tumor-associated light and heavy Ab chains, genetically grafted onto a common human IgG1 scaffold. Each immunogen was produced in Nicotiana benthamiana plants using twin magnICON vectors expressing the light and heavy chains of the idiotypic Ab. Each purified Ab was chemically linked to the carrier protein keyhole limpet hemocyanin (KLH) to form a conjugate vaccine. The vaccines were administered to FL patients over a series of ≥ 6 subcutaneous injections in conjunction with the adjuvant Leukine (GM-CSF). The 27 patients enrolled in the study had previously received non-anti-CD20 cytoreductive therapy followed by ≥ 4 months of immune recovery prior to first vaccination. Of 11 patients who became evaluable at study conclusion, 82% (9/11) displayed a vaccine-induced, idiotype-specific cellular and/or humoral immune response. No patients showed serious adverse events (SAE) related to vaccination. The fully scalable plant-based manufacturing process yields safe and immunogenic personalized FL vaccines that can be produced within weeks of obtaining patient biopsies.

AB - We report the first evaluation of plant-made conjugate vaccines for targeted treatment of B-cell follicular lymphoma (FL) in a Phase I safety and immunogenicity clinical study. Each recombinant personalized immunogen consisted of a tumor-derived, plant-produced idiotypic antibody (Ab) hybrid comprising the hypervariable regions of the tumor-associated light and heavy Ab chains, genetically grafted onto a common human IgG1 scaffold. Each immunogen was produced in Nicotiana benthamiana plants using twin magnICON vectors expressing the light and heavy chains of the idiotypic Ab. Each purified Ab was chemically linked to the carrier protein keyhole limpet hemocyanin (KLH) to form a conjugate vaccine. The vaccines were administered to FL patients over a series of ≥ 6 subcutaneous injections in conjunction with the adjuvant Leukine (GM-CSF). The 27 patients enrolled in the study had previously received non-anti-CD20 cytoreductive therapy followed by ≥ 4 months of immune recovery prior to first vaccination. Of 11 patients who became evaluable at study conclusion, 82% (9/11) displayed a vaccine-induced, idiotype-specific cellular and/or humoral immune response. No patients showed serious adverse events (SAE) related to vaccination. The fully scalable plant-based manufacturing process yields safe and immunogenic personalized FL vaccines that can be produced within weeks of obtaining patient biopsies.

UR - http://www.scopus.com/inward/record.url?scp=84942278930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942278930&partnerID=8YFLogxK

U2 - 10.1155/2015/648143

DO - 10.1155/2015/648143

M3 - Article

C2 - 26425548

AN - SCOPUS:84942278930

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 648143

ER -